From: Fine-tuning anti-tumor immunotherapies via stochastic simulations
Par. | Value | Unit | Description |
---|---|---|---|
r | 0.18 | days -1 | baseline growth rate of the tumor |
b | 10-9 | ml -1 | carrying capacity of the tumor |
a | 1 | ml/days | baseline strength of the killing rate by immune effectors |
c | 10-4 | days -1 | tumor antigenicity |
V | 3.2 | Ml | blood and bone marrow volumes for leukemia |
g T | 105 | ml -1 | 50% reduction factor of the killing rate by immune effectors |
g E | 2 · 107 | pg/l | 50% reduction factor of IL-stimulated growth rate of effectors |
g I | 103 | ml -1 | 50% reduction factor of production rate of interleukins |
p E | 0.1245 | days -1 | baseline strength of the IL-stimulated growth rate of effectors |
p I | 5 | pg/days | baseline strength of production rate of interleukins |
μ E | 0.03 | days -1 | inverse of average lifespan of effectors |
μ I | 10 | days -1 | loss/degradation rate of IL2 |